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Abstract
Background: More than half of the patients selected based on KRAS mutation status fail to respond to the treatment
with cetuximab in metastatic colorectal cancer (mCRC). We designed a study to identify additional biomarkers that
could act as indicators for cetuximab treatment in mCRC.
Methods: We investigated 58 tumor samples from wild type KRAS CRC patients treated with cetuximab plus irinotecan
(CI). We conducted the genotyping for mutations in either BRAF or PIK3CA and profiled comprehensively the
expression of 522 kinase genes.
Results: BRAF mutation was detected in 5.1 % (3/58) of patients. All 50 patients showed wild type PIK3CA. Gene
expression patterns that categorized patients with or without the disease control to CI were compared by supervised
classification analysis. PSKH1, TLK2 and PHKG2 were overexpressed significantly in patients with the disease control to IC.
The higher expression value of PSKH1 (r = 0.462, p < 0.001) and TLK2 (r = 0.361, p = 0.005) had the significant correlation
to prolonged PFS.
Conclusion: The result of this work demonstrated that expression nature of kinase genes such as PSKH1, TLK2 and
PHKG2 may be informative to predict the efficacy of CI in wild type KRAS CRC. Mutations in either BRAF or PIK3CA
were rare subsets in wild type KRAS CRC.
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Background
Colorectal cancer (CRC) has been a significant cause of
morbidity and mortality throughout the world [1]. Meta-
static CRC (mCRC) is associated with a particularly poor
prognosis. Despite progress in cytotoxic chemotherapy
during past decade, the five year survival rate for mCRC
remains below 10 % [2]. There have been recent and
rapid advances in the development of agents targeted
against components of receptor tyrosine kinase signaling
cascades for use in cancer-therapy. A monoclonal anti-
body (mAb) against epidermal growth factor receptor
(EGFR), referred to as cetuximab, is a product of this
movement, and has been implemented to treat selected
mCRC patients.
However, only 10–20 % of the selected mCRC patients
benefit from anti-EGFR therapy [3–6], highlighting a
distinct need for individualized treatment. Following the
discovery that mutations in KRAS are associated with re-
sistance to anti-EGFR treatment, determination of KRAS
status is now recommended in mCRC patients before
starting anti-EGFR therapies. Despite the application of
these selective strategies, less than half of the chosen
wild type KRAS patient population benefits from anti-
EGFR treatment [7–9]. More recently, other oncogenic
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alterations such as mutations in BRAF and PIK3CA
were identified as candidates associated with resist-
ance to anti-EGFR therapies in wild type KRAS pa-
tients [8, 10–13]. However, there is still a need to
identify and confirm additional biomarkers that can be
used to more accurately select wild type mCRC pa-
tients that will respond to anti-EGFR therapy.
Protein kinases control many cellular processes includ-
ing metabolism, transcription, cell cycle progression,
cytoskeletal rearrangement, cell movement, apoptosis,
and differentiation [14, 15]. Therefore, protein kinases
are essential targets for molecular therapy. Indeed, vari-
ous protein kinase inhibitors have been shown to be
effective against cancer cells. Cancers often result from
the interconnectivity of complex pathways, some of
which are not well understood. For this reason, we
surmise that the anti-tumor activity of cetuximab may
be affected by various kinase genes involved different
pathways.
In order to identify additional selective biomarkers for
CI indication, we genotyped wild type KRAS colorectal
tumor samples from patients that received CI treatment
for mutations in either BRAF or PIK3CA, and profiled




Fifty-eight mCRC patients with CI, for whom collection
of tumor samples was part of their routine care and
treatment, were enrolled for this analysis. Patients were
treated by CI after confirming KRAS mutational status
(wild type). The tumor samples were sufficient to study
additional biomarkers, such as genotyping for BRAF
and PIK3CA and targeted gene expression profiling. In
all cases, we reviewed patient age at diagnosis, gender,
Eastern Cooperative Oncology Group (ECOG) perform-
ance status, the number of involved organs, metastatic
site, and chemotherapy data. All hematoxylin and eosin
stained slides were reviewed, and representative paraffin
blocks were selected for further studies.
DNA extraction and mutation analysis for BRAF and
PIK3CA
DNA was extracted from five 10-μm thick formalin
fixed paraffin embedded (FFPE) sections containing a
representative portion of each tumor block, using the
QIAamp DNA Mini kit (Qiagen, Hilden, Germany). A
pathologist reviewed each slide and verified the pres-
ence of adequate tumor tissue with greater than 50 %
representative malignant cells.
Peptide nucleic acid-locked nucleic acid (PNA–LNA)
PCR clamp reactions were carried out using the PNA-
Clamp™ BRAF, and PNA-Clamp™ PIK3CA Mutation
Detection Kits (Panagene, Inc., Daejeon, Korea), as de-
scribed previously. Briefly, this reaction consists of the
following; all reactions were done in 20 μl volumes using
10–25 ng template DNA, primer and PNA probe set,
and SYBR Green PCR master mix. All necessary
reagents are included with the kit. Real-time PCR reac-
tions of PNA-mediated clamping PCR were performed
using a CFX 96 system (Bio-Rad, USA). PCR conditions
started with a 5 min hold at 94 °C, followed by 40 cycles
of 94 °C for 30 s, 70 °C for 20 s, 63 °C for 30 s, and
72 °C for 30 s. Detection of each of mutation in BRAF
exon 15, and 3 mutations in PIK3CA exons 2 & 9 was
possible using one-step PNA-mediated real-time PCR
clamping.
Targeted gene expression profiling
The Nanostring-based multigene assay was performed in
tissue samples of 58 patients who received cetuximab-
based therapy for mCRC. Total RNA was extracted from
one or two sections of 4-μm thick FFPE tumor sections
using the High Pure RNA Paraffin kit (Roche Diagnostic,
Mannheim, Germany) after removing non-tumor ele-
ments by manual macrodissection guided by hematoxylin
and eosin stained slides. nCounter® GX Human Kinase Kit
(NanoString Technologies, Seattle, WA, USA) was used
for gene expression analyses. One hundred nanogram of
total RNA was hybridized with the pre-built code set of
522 genes for 18 h at 65 °C and processed according to
manufacturer’s instruction [16].
Ethics statement
The institutional review board of the Samsung Medical
Center (SMC) approved the process of acquiring tissue
samples in mCRC patients with cetuximab-based ther-
apy. All study participants provided a written informed
consent form, which was approved by the institutional
review board. The methods in this study were carried
out in accordance with the approved guidelines by SMC
and all experimental protocols were approved by the
ethics committees of SMC.
Statistical analysis
To discover differential expression of 522 kinase genes
between two groups (partial response plus stable disease
vs. progressive disease), t-test is applied after the data is
normalized by quantile method. Response definitions
that differentiated two groups were according to
Response Evaluation Criteria in Solid Tumors (RECIST)
1.1. To identify gene set that is associated with disease
control, t-test statistics of 522 genes were further
assessed by Pathway Activity inference using Condition-
responsive genes (PAC). Spearman’s test was used to as-
sess the correlation between progression free survival
(PFS) and expression vales of selected kinase genes that
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related to the disease control for cetuximab. Results
were considered statistically significant when p-values
were < 0.05. Gene expression difference analysis and
pathway analysis were performed using R (version 2.15
and package 2.10) (http://www.R-project.org), and other
statistical analyses were performed using SPSS software
(SPSS Inc., Chicago, IL, USA).
Pathway association analysis
To identify gene set that associated with disease control
(partial response plus stable disease vs. progressive disease),
we conducted Efron-Tibshirani’s gene set analysis (GSA)
maxmean test embedded in the BRB Array Tool. We ex-
amined 92 gene sets in Biocarta Pathway database and the
threshold of determining significant gene sets is 0.01.
Results
Clinicopathological features
As summarized in Table 1, 58 wild type KRAS mCRC
patients of a median age of 59 years (range, 39–91) re-
ceived CI treatment. The study included 33 (56.9 %)
male and 25 (43.1 %) female patients. Most of the
patients (96.6 %) had a good performance status (ECOG
1) and over half of the patients (75.9 %) had metastatic
disease at diagnosis. More than half of patients (51.7 %)
had three or more metastatic lesions and 91.4 % received
CI as third or more line treatment. Only 18 patients
(31 %) had prior anti-VEGF therapy before CI.
Frequency of BRAF and PIK3CA mutations
BRAF mutation status was assessed in 54 of 58
(93.1 %) patients. Three of these (5.6 %) patients har-
bored BRAF mutations (V600E). PIK3CA mutation sta-
tus was evaluated in 50 of 58 (86.2 %) patients, and all
50 patients showed wild type PIK3CA (Table 1). CI did
not reveal the anti-tumor effect in all 3 patients with
BRAF mutation.
Expression of kinase genes and cetuximab treatment
outcome
Among the 58 patients receiving cetuximab-based ther-
apy, 21 achieved a confirmed partial response and nine
had stable disease, resulting in an overall response rate
(ORR) of 36.2 % (21/58) and disease control rate (DCR)
51.7 % (30/58) (Table 2). There were 522 kinase genes
analyzed by nCounter assay and a supervised method
was used to find statistically significant differentially
expressed genes between patients with and without the
disease control for CI. A hierarchical clustering analysis
was then performed on the samples based on expression
value of 522 genes in 58 patients (Fig. 1). We found
three kinase genes such as PSKH1, TLK2 and PHKG2
that were presented significantly higher expression levels
in patients with the disease control to CI (Fig. 2).
Table 1 Baseline characteristics of the patients enrolled in this
study
Characteristics Number of patients N (%)










Number of metastatic sites
≤2 25 (43.1)
2< 33 (56.9)















Table 2 Treatment outcomes of cetuximab therapy and the
corresponding number of patients
Treatment outcomes Number of patients N (%)
Response
Complete response 0 (0.0)
Partial response 21 (36.2)
Stable disease 9 (15.5)
Progressive disease 28 (48.3)
Response rate 21 (36.2)
Disease control rate 30 (51.7)
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Fig. 1 Supervised clustering of 522 kinase genes that are differentially expressed between patients with and without tumor response to CI and
between patients with and without the disease control to CI. RR; complete response plus partial response: DCR; RR plus stable disease
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Progression free survival and expression of PSKH1, TLK2
and PHKG2
All 58 patients with cetuximab-based therapy were ana-
lyzed for progression free survival (PFS) and exhibited a
median PFS of 2.4 months (95 % CI, 0.0–7.2) (Fig. 3). The
correlation was analyzed between PFS and the expression
values of PSKH1, TLK2 and PHKG2. The higher expres-
sion value of PSKH1 (r = 0.462, p < 0.001) (Fig. 4a) and
TLK2 (r = 0.361, p = 0.005) (Fig. 4b) had the significant
correlation to prolonged PFS. However, the statistically
significant correlation was not observed between PHK2G2
and PFS (r = 0.236, p = 0.075) (Fig. 4c).
Signaling pathways related to the anti-tumor activity of CI
We performed pathway analysis using gene set enrich-
ment analysis for expression of 522 kinase genes. For the
Fig. 2 Kinase genes (PSKH1, TLK2 and PHKG2) that were differentially expressed between patients with and without the disease control to CI
Fig. 3 Kaplan-Meier estimate of progression free survival (PFS)
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disease-controlled cohort, 3 out of 92 investigated
Biocarta pathway gene sets passed the 0.01 significance
threshold as verified by Efron-Tibshirani’s GSA max-
mean test. These included the CCR3 signaling pathway,
the cdMac signaling pathway, and the integrin signaling
pathway (Table 3).
Discussion
Despite exclusion of 30–40 % of patients with KRAS
mutant tumors, cetuximab-based therapy fail in more
than half of CRC patients harboring wild type KRAS
[4, 9, 17–19]. Recently, mutations in other downstream
effectors of the EGFR pathway, such as BRAF, NRAS,
and PIK3CA have also been implicated as possible pre-
dictors for anti-EGFR response [12, 18, 20, 21]. Over-
all, the benefit of analyzing these candidates has been
difficult to determine due to low mutation frequencies
for individual markers. In an attempt to identify add-
itional biomarkers for the efficacy of cetuximab-based
therapy in CRC patients with wild type KRAS, we
performed targeted gene expression profiling for 522
kinase genes in addition to genotyping for BRAF and
PIK3CA. Our analysis suggested that the overexpres-
sion of PSKH1, TLK2 and PHKG2 may be a considered
a potential biomarker to predict the efficacy of CI in
wild type KRAS CRC. Moreover, the higher expression
Fig. 4 The correlation between PFS and the expression value of (a) PSKH1, (b) TLK2 and (c) PHKG2
Table 3 Results of the gene-set enrichment analysis of the
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value of PSKH1 (r = 0.462, p < 0.001) and TLK2 (r = 0.361,
p = 0.005) had the significant correlation to prolonged
PFS. However, among 522 kinase genes, any gene didn’t
have significant prognostic value for overall survival (OS).
We also conducted the multivariate analysis (Cox pro-
portional hazard modeling) for PFS with clinical vari-
able and expression nature of kinase genes such as
PSKH1, TLK2 and PHKG2. Univariate analysis showed
that prolonged PFS was significantly associated with
metastatic sites of ≤ 2, and expressed of PSKH1, TLK2
and PHKG2. In multivariate analysis, only expressed of
PSKH1 (hazard ratio [HR], 2.219; 95 % confidence
interval [CI], 1.085 TO 4.541; p = 0.029) was signifi-
cantly with prolonged PFS.
We used an nCounter assay to analyze the expression
of kinase genes. The nCounter assay can profile 522
human kinase genes in one reaction tube with only
100 ng of total RNA. Previously, we compared the re-
sults of an nCounter assay with immunohistochemistry
results using three biomarkers (EGFR, HER2 and MET)
in a gastric cancer (GC) model [22]. Relative to immu-
nohistochemistry findings, the NanoString-based assay
sensitivities and specificities were 85.7 % and 82.8 % for
EGFR, 100 % and 97.2 % for HER2, and 100 % and
100 % for MET, respectively. Hence, nCounter assays
may be feasible as a relatively reliable option in the
clinic, where only small amount of RNA (~100 ng) can
be rendered from paraffin-embedded tissues. Based on
our previous study, NanoString-based kinase assay has
been used as a feasible screening tool for initially identi-
fying patients who have GC with overexpressed drug
targets in our institution. This study suggested that
nCounter assays could be used efficiently as a platform
for implementing personalized medicine of CRC.
PSKH1 is a 424 amino acids long ubiquitously
expressed autophosphorylating humane protein serine
kinase [23, 24]. PSKH1 has been known to have a useful
structural and regulatory role in the maintenance of the
Golgi apparatus [25]. TLK2 is a nuclear serine/threonine
kinase which is a cell cycle check point regulating chro-
matin assembly and is inactivated in response to DNA
damage [26]. Although the higher expression value for
PSKH1 and TLK2 is likely to be related to prolonged
PFS as well as antitumor effect for CI in CRC patients
in this analysis, the molecular determinants for overex-
pression for PSKH1 and TLK2 are unknown for the
effect of cetuximab. Further functional analysis of these
kinase genes is needed to apply these markers in clin-
ical practice.
Assessment of some mutations could improve the ob-
jective response rate; objective response rates were 24.4 %
in unselected population, 36.3 % in population harboring
the wild type KRAS, and 41.2 % in the KRAS, BRAF,
NRAS, and PIK3CA exon 20 wild type populations [18].
However, cetuximab still fails to meet expectations in
more than half of patients who were selected via genotyp-
ing of multiple genes. There are some limitations in our
study. A small sample size, heterogeneous patient popula-
tion, retrospective nature, and limited validated data didn’t
allow us to draw any significant conclusions. Especially,
our study included only 3 patients with BRAF mutation.
Thus, the role of BRAF mutation as predictive marker
for cetuximab needs to be validated and studied. Tissue
availability was also a potential limitation of the current
retrospective biomarker-analysis. It is better to verify
the PSKH1, TLK2, and PHKG2 expression identified by
nCounter assay in tissues using independent methods
such as in situ hybridization, immune histochemistry or
RT-qPCR. However, patients analyzed in this study had
refractory cancer. Among these patients, it was difficult
to get the tumor tissue for biomarker-analysis. Never-
theless, our attempts to whether expression of kinase
genes could serve as biomarkers for the efficacy of
cetuximab therapy in wild type KRAS CRC patients is
worth noting.
Many crucial signaling pathways become dysregulated
during cancer initiation and progression. Identifying the
pathways involved and quantifying their deregulation is
an important step toward understanding carcinogenesis
[27–30]. Because advanced therapies target specific path-
ways, pathway-level understanding is also a necessity in
the development of personalized cancer treatments. Previ-
ously, we found that KRAS mutant CRC patients with low
RAS signature scores were likely to benefit from treatment
with cetuximab, irinotecan plus simvastatin [31]. This
finding suggested that differential RAS signaling in KRAS
mutant CRC patients is a useful biomarker for choosing
the proper treatment regimen. Based on our analysis,
CCR3, cdMac, and integrin pathways are significantly
associated with the activity of cetuximab as the down-
regulation of these pathways correlated with an observed
increase in cetuximab efficacy, though these results must
be validated. Additional, work will also need to be done to
evaluate whether the CCR3, cdMac, and integrin pathways
are interconnected with the EGFR signaling that was
known as the key pathway for the effect of cetuximab.
Many new investigational agents, such as inhibitors of
MAP2K, PI3K, mTOR, EGFR, and BRAF will be ex-
tremely useful for elucidating these networks [32]. These
pathway-based approaches will be used as novel algo-
rithms for precision medicine.
In conclusion, our study suggested that expression na-
ture of kinase genes such as PSKH1, TLK2 and PHKG2
may be informative to predict the efficacy of CI in wild
type KRAS CRC. In addition to known EGFR pathway,
the CCR3, cdMac, and integrin pathways may also be use-
ful in predicting cetuximab response in these patients.
Our findings warrant further independent validation. In
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the future, multiple-biomarker assessment will be needed
in mCRC patients in order to optimize identification of
patients that will benefit from cetuximab.
Conclusion
The result of this work demonstrated that CI did not have
anti-tumor activity in BRAF mutant CRC. Additionally,
expression nature of kinase genes such as PSKH1, TLK2
and PHKG2 may be informative to predict the efficacy of
CI in wild type KRAS CRC.
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